PPHM released news that it will collaborate with Astrazeneca, combining PPHM's PS_ targeting drug Bavituximab and Astrazdeneca's investigational anti PD-L1 immune checkpoint inhibitor Durvalumab. The planned Phase I/Ib trial will evaluate the safety and efficacy of Bavituximab in combination with Durvalumab in multiple solid tumours
In the course of less than a year, PPHM has secured collaboration with several prominent establishments, including MSK and BMS.
This goes to show that gradually Bavituximab is gaining acceptance as an important combination in imunotheraphy drugs targeting cancer and tumours.
My disclosure: I am long PPHM.
No comments:
Post a Comment